Zymeworks Announces Participation in Upcoming Investor Conferences
Rhea-AI Summary
Zymeworks (Nasdaq: ZYME) announced participation in several upcoming investor events focused on oncology and healthcare.
Management will join virtual and in-person fireside chats and one-on-one meetings at the 2026 Stifel Virtual Targeted Oncology Forum, TD Cowen 7th Annual Oncology Innovation Summit, and 2026 Jefferies Global Healthcare Conference.
Positive
- None.
Negative
- None.
News Market Reaction – ZYME
In the May 13 session, ZYME gained 2.80%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
- 2026 Stifel Virtual Targeted Oncology Forum: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on May 20 at 9:00 am Eastern Time (ET) virtually.
- TD Cowen 7th Annual Oncology Innovation Summit: Zymeworks’ management will participate in a fireside chat on May 27 at 4:30 pm ET virtually.
- 2026 Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on June 3 at 8:45 am ET in New York, NY.
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks’ asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com
